FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282959892> ?p ?o ?g. }

• W4282959892 endingPage "1263" @default.
• W4282959892 startingPage "1263" @default.
• W4282959892 abstract "PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020. However, PD-L1 inhibitor Tecentriq combined with albumin paclitaxel using the similar strategy failed to achieve the expected effect. Therefore, it is still necessary to explore new effective immunotherapy and chemotherapy-based combined strategies. We developed a cell membrane-derived programmed death-ligand 1(PD-1) nanovesicle to encapsulate low-dose gemcitabine (PD-1&GEM NVs) to study the effect on breast cancer in vitro and in vivo. We found that engineered PD-1&GEM NVs could synergistically inhibit the proliferation of triple-negative breast cancer, which interacted with PD-L1 in triple-negative breast cancer to disrupt the PD-L1/PD-1 immune inhibitory axis and promoted cancer cell apoptosis. Moreover, PD-1&GEM NVs had better tumor targeting ability for PD-L1 highly-expressed TNBC cells, contributing to increasing the drug effectiveness and reducing toxicity. Importantly, gemcitabine-encapsulated PD-1 NVs exerted stronger effects on promoting apoptosis of tumor cells, increasing infiltrated CD8+ T cell activation, delaying the tumor growth and prolonging the survival of tumor-bearing mice than PD-1 NVs or gemcitabine alone. Thus, our study highlighted the power of combined low-dose gemcitabine and PD-1 in the nanovesicles as treatment to treat triple-negative breast cancer." @default.
• W4282959892 created "2022-06-17" @default.
• W4282959892 creator A5013847668 @default.
• W4282959892 creator A5023562699 @default.
• W4282959892 creator A5028141611 @default.
• W4282959892 creator A5029424879 @default.
• W4282959892 creator A5038309864 @default.
• W4282959892 creator A5038539967 @default.
• W4282959892 creator A5055256736 @default.
• W4282959892 creator A5057498913 @default.
• W4282959892 creator A5065065428 @default.
• W4282959892 creator A5068593978 @default.
• W4282959892 creator A5069138081 @default.
• W4282959892 date "2022-06-14" @default.
• W4282959892 modified "2023-10-15" @default.
• W4282959892 title "PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell" @default.
• W4282959892 cites W2019280422 @default.
• W4282959892 cites W2101653483 @default.
• W4282959892 cites W2114235650 @default.
• W4282959892 cites W2181940340 @default.
• W4282959892 cites W2292383635 @default.
• W4282959892 cites W2326555481 @default.
• W4282959892 cites W2340636398 @default.
• W4282959892 cites W2378121956 @default.
• W4282959892 cites W2464620827 @default.
• W4282959892 cites W2559377932 @default.
• W4282959892 cites W2600452401 @default.
• W4282959892 cites W2733692754 @default.
• W4282959892 cites W2790574591 @default.
• W4282959892 cites W2792073784 @default.
• W4282959892 cites W2799662486 @default.
• W4282959892 cites W2885447533 @default.
• W4282959892 cites W2891557077 @default.
• W4282959892 cites W2897422388 @default.
• W4282959892 cites W2911718257 @default.
• W4282959892 cites W2941157893 @default.
• W4282959892 cites W2942052760 @default.
• W4282959892 cites W2982315700 @default.
• W4282959892 cites W3094271383 @default.
• W4282959892 cites W3096115343 @default.
• W4282959892 cites W3097851508 @default.
• W4282959892 cites W3109853980 @default.
• W4282959892 cites W3112277151 @default.
• W4282959892 cites W3112973466 @default.
• W4282959892 cites W3128131226 @default.
• W4282959892 cites W3128646645 @default.
• W4282959892 cites W3134220725 @default.
• W4282959892 cites W3175173749 @default.
• W4282959892 cites W3208285510 @default.
• W4282959892 cites W3210242491 @default.
• W4282959892 cites W4205724345 @default.
• W4282959892 cites W4211032970 @default.
• W4282959892 cites W4213259262 @default.
• W4282959892 doi "https://doi.org/10.3390/pharmaceutics14061263" @default.
• W4282959892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35745835" @default.
• W4282959892 hasPublicationYear "2022" @default.
• W4282959892 type Work @default.
• W4282959892 citedByCount "3" @default.
• W4282959892 countsByYear W42829598922022 @default.
• W4282959892 countsByYear W42829598922023 @default.
• W4282959892 crossrefType "journal-article" @default.
• W4282959892 hasAuthorship W4282959892A5013847668 @default.
• W4282959892 hasAuthorship W4282959892A5023562699 @default.
• W4282959892 hasAuthorship W4282959892A5028141611 @default.
• W4282959892 hasAuthorship W4282959892A5029424879 @default.
• W4282959892 hasAuthorship W4282959892A5038309864 @default.
• W4282959892 hasAuthorship W4282959892A5038539967 @default.
• W4282959892 hasAuthorship W4282959892A5055256736 @default.
• W4282959892 hasAuthorship W4282959892A5057498913 @default.
• W4282959892 hasAuthorship W4282959892A5065065428 @default.
• W4282959892 hasAuthorship W4282959892A5068593978 @default.
• W4282959892 hasAuthorship W4282959892A5069138081 @default.
• W4282959892 hasBestOaLocation W42829598921 @default.
• W4282959892 hasConcept C121608353 @default.
• W4282959892 hasConcept C126322002 @default.
• W4282959892 hasConcept C143998085 @default.
• W4282959892 hasConcept C167672396 @default.
• W4282959892 hasConcept C185592680 @default.
• W4282959892 hasConcept C190283241 @default.
• W4282959892 hasConcept C203014093 @default.
• W4282959892 hasConcept C2776694085 @default.
• W4282959892 hasConcept C2777292972 @default.
• W4282959892 hasConcept C2777701055 @default.
• W4282959892 hasConcept C2780110267 @default.
• W4282959892 hasConcept C2780258809 @default.
• W4282959892 hasConcept C502942594 @default.
• W4282959892 hasConcept C530470458 @default.
• W4282959892 hasConcept C55493867 @default.
• W4282959892 hasConcept C71924100 @default.
• W4282959892 hasConcept C8891405 @default.
• W4282959892 hasConcept C98274493 @default.
• W4282959892 hasConceptScore W4282959892C121608353 @default.
• W4282959892 hasConceptScore W4282959892C126322002 @default.
• W4282959892 hasConceptScore W4282959892C143998085 @default.
• W4282959892 hasConceptScore W4282959892C167672396 @default.
• W4282959892 hasConceptScore W4282959892C185592680 @default.
• W4282959892 hasConceptScore W4282959892C190283241 @default.
• W4282959892 hasConceptScore W4282959892C203014093 @default.

• next